Metformina + Sitagliptina Pentafarma

Metformin hydrochloride, the active ingredient in Metformina + Sitagliptina Pentafarma, is a biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients, often in combination with diet and exercise. GNH USA supplies Metformina + Sitagliptina Pentafarma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformina + Sitagliptina Pentafarma is indicated for the management of type 2 diabetes mellitus and related glycemic control pathways.

- Type 2 diabetes mellitus: lowers blood glucose and HbA1c levels. - Inadequate response to metformin alone: adds DPP‑4 inhibition to improve glycemic control. - Adjunct to diet and exercise: supports overall management of type 2 diabetes.

The combination may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Metallic taste in the mouth. - Headache. - Decreased appetite.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Severe hypoglycemia: especially when used with insulin or sulfonylureas. - Pancreatitis: inflammation of the pancreas requiring immediate medical attention. - Severe allergic reactions: such as rash, itching, swelling, or difficulty breathing. - Hepatic or renal failure: may be precipitated in susceptible individuals.

Use of this fixed‑dose combination requires careful clinical assessment. - Renal function: evaluate before initiation and monitor periodically. - Lactic acidosis risk: avoid in patients with significant hepatic impairment, severe infection, or hypoxia. - Hypoglycemia risk: exercise caution when combined with insulin or sulfonylureas. - Pregnancy and lactation: safety not established; prescribe only if benefits outweigh potential risks. - Vitamin B12 monitoring: long‑term metformin therapy may reduce absorption, requiring periodic assessment. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Metformina + Sitagliptina Pentafarma can interact with several medicines, necessitating monitoring.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of severe hypoglycemia. - Iodinated contrast agents: may precipitate renal dysfunction when combined with metformin. - Cimetidine: can raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - ACE inhibitors or ARBs: require renal function monitoring. - Rifampin: may reduce sitagliptin plasma levels, potentially diminishing efficacy.